BIO letter to HHS Secretary Xavier Becerra on the importance of funding R&D for COVID-19 therapeutics at Biomedical Advanced Research and Development Agency (BARDA).
June 25, 2021
The partnership between the biopharmaceutical industry and the U.S. Government is largely responsible for where we are with the COVID-19 pandemic today. In just 16 months from the declaration of the pandemic, cases have dramatically dropped as more than 50% of U.S. adults have gotten vaccinated, and we now have proven treatments for cases of COVID-19. Despite this success, BIO and our members are concerned by the May 2021 change to the Biomedical Advanced Research and Development Agency (BARDA) Broad Agency Announcement (BAA) that suspends prioritization of Area of Interest (AOI) 9.2 -COVID-19 Therapeutics.
Download Full Comments Below
BIO letter to HHS Secretary Xavier Becerra on the importance of funding R&D for COVID-19 therapeutics at Biomedical Advanced Research and Development Agency (BARDA).
BIO and BIO members are urging lawmakers to enact a short-term extension of the MCM-PRV program while Congress is waiting to address a full reauthorization with PAHPA.
BIO has submitted comments to the Office of Science & Technology Policy on how regulations underpinning the Coordinated Framework for the Regulation of Biotechnology can better facilitate the use of biotechnology to stimulate the economy…
The partnership between the biopharmaceutical industry and the U.S. Government is largely responsible for where we are with the COVID-19 pandemic today. In just 16 months from the declaration of the pandemic, cases have dramatically dropped as more than 50% of U.S. adults have gotten vaccinated, and we now have proven treatments for cases of COVID-19. Despite this success, BIO and our members are concerned by the May 2021 change to the Biomedical Advanced Research and Development Agency (BARDA) Broad Agency Announcement (BAA) that suspends prioritization of Area of Interest (AOI) 9.2 -COVID-19 Therapeutics.